

Listing of Claims:

1. (Cancelled)
2. (Previously Presented) The method of claim 11 wherein the newborn subject is a mammal in the first four weeks after birth.
3. (Cancelled)
4. (Cancelled)
5. (Previously Presented) The method of claim 11 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.
6. (Previously Presented) The method of claim 11 wherein the medicament is in gaseous form.
7. (Cancelled)
8. (Previously Presented) The method of claim 11 wherein the medicament is in liquid form.
9. (Cancelled)
10. (Cancelled)
11. (Currently Amended) A method of providing analgesia in a human newborn subject, the method comprising administering a therapeutically effective amount of an analgesic to a human newborn subject experiencing pain or stress sufficient to necessitate administration of the analgesic, wherein the analgesic is xenon. ~~in need of analgesia a therapeutically effective amount of xenon.~~

12. (Currently Amended) A method of providing analgesia in a human fetal subject, the method comprising administering a therapeutically effective amount of an analgesic to a ~~the~~ mother of a ~~the~~ human fetal subject, the fetal subject experiencing pain or stress sufficient to necessitate administration of the analgesic, wherein the analgesic is xenon ~~in need of analgesia, a therapeutically effective amount of xenon~~ ~~the fetal subject.~~

13. (Previously Presented) A method accordingly to claim 11 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

14. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

15. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a lipid emulsion.

16. (Previously Presented) A method according to claim 11 wherein the xenon is administered intravenously, neuraxially or transdermally.

17. (Previously Presented) A method accordingly to claim 12 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

18. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

19. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a lipid emulsion.

20. (Previously Presented) A method according to claim 12 wherein the xenon is administered intravenously, neuraxially or transdermally.

21. (Previously Presented) The method according to claim 12, wherein the xenon is administered to the mother prior to labor.
22. (Previously Presented) The method according to claim 12, wherein the xenon is administered to the mother during labor.
23. (Previously Presented) The method of claim 5, wherein the further analgesic agent is an alpha-2-adrenergic agonist, an opiate, or a non-steroidal anti-inflammatory drug.
24. (Previously Presented) The method of claim 5, wherein the sedative or anaesthetic agent promotes GABAergic activity.